Learning curve in circular multipolar phased radiofrequency ablation of atrial fibrillation

Authors: Mihran Martirosyan, Alexandra Kiss, Edina Nagy-Baló, Gábor Sándorfi, Diana Tint, István Édes, Zoltán Csánádi

DOI: 10.5603/CJ.a2014.0085

Article type: Original articles - Arrhythmias and devices

Submitted: 2014-08-13

Accepted: 2014-09-21

Published online: 2014-11-14

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
Learning curve in circular multipolar phased radiofrequency ablation of atrial fibrillation

Short title: Learning curve in phased RF ablation

Mihran Martirosyan, Alexandra Kiss, Edina Nagy-Baló, Gábor Sándorfi, Diana Tint, István Édes, Zoltán Csanádi

Institute of Cardiology, University of Debrecen, Debrecen, Hungary

Address for correspondence: Zoltan Csanadi MD, PhD, FESC, Address: Institute of Cardiology, University of Debrecen, 22 Móricz Zs. Krt., Debrecen, Hungary, H-4032, tel: +36-209277231; fax: +3652414928, e-mail: drcsanadi@hotmail.com

Abstract

Background: Although atrial fibrillation (AF) ablation is considered a technically challenging procedure, studies on the learning curve of different pulmonary vein isolation (PVI) techniques are limited. We investigated the time-dependent changes in procedural parameters, complication rates, and in the 1-year clinical outcome during our initial experience with circular multipolar phased radiofrequency (RF) ablation.

Methods and Results: The first 132 consecutive patients (40 female; age: 56.6, SD: 10.4 years) who underwent PVI with phased RF ablation for paroxysmal or persistent AF at our center were included in the study. Procedural parameters and atrial arrhythmia-free survival were compared in the first, second and third 44 successive patients. All PVs were successfully isolated in 44 (100%), 41 (93.8 %) and 42 (95.5 %) patients in Tierce 1, 2 and 3, respectively, (p=0.233). The number of RF applications (per vein) required for isolation and fluoroscopy times demonstrated a significant decrease with experience, and a trend for lower procedure times in Tierces 2 and 3 were also observed. Atrial arrhythmia-free survival rates at 12 months postablation were 68.18% , 75%, and 70.75% in Tierce 1, Tierce 2 and Tierce 3, respectively (p=0.772). Pericardial tamponade requiring percutaneous subxiphoid drainage occured in 1 patient (Tierce 3) as the only significant procedural complication.
Conclusions: A learning curve effect was demonstrated in fluoroscopy times and in the number of RF applications but not in the acute success and in the long-term arrhythmia-free survival with circular multipolar RF ablations.

Key words: atrial fibrillation, phased RF ablation, learning curve, arrhythmia-free survival

Introduction

Catheter ablation for atrial fibrillation (AF) has emerged as an alternative to antiarrhythmic drug (AAD) therapy after the failure of at least one AAD, or even as the first line of treatment in selected cases\(^1{-}^3\). Although a wide variety of ablation techniques have been used to treat AF, it is generally agreed that the cornerstone of any transcatheter procedure is the electrical isolation of all pulmonary veins (PVs). This is currently most commonly achieved by encircling the PVs with focal radiofrequency (RF) lesions under the guidance of a 3-dimensional electroanatomical mapping or navigation system. This point-by-point ablation technique requires extensive operator experience for efficacy and safety, and is usually associated with long procedure times. Novel methods aiming at simpler and faster PV isolation (PVI) have therefore been developed in recent years, including cryoballoon (CB) ablation\(^4{-}^5\) and multipolar RF ablation with the circular PV ablation catheter (PVAC)\(^6{-}^9\). These “single-shot” techniques were designed to create a circular ablation lesion around the PVs after the appropriate positioning of the ablation catheter at the ostium or at the antra of each PV. A number of studies have demonstrated comparable levels of success and safety profile, but shorter procedure times with these simplified methods than with the conventional point-by-point ablation\(^10{-}^13\).

With the continuous increase in the number of AF ablation world-wide, the procedure is being introduced into new and less experienced centers. Efficacy and periprocedural complications are known to improve with experience in any invasive procedure including AF ablation although the learning curve effect has not been extensively evaluated. Sairaku et al.\(^14\) have reported a significantly higher incidence of procedure-related complications and a lower arrhythmia-free survival at 6 month follow-up with the double Lasso catheter-guided encircling pulmonary vein isolation in the first 52 as compared with the following 156 patients who underwent the ablation. Wojcik et al.\(^15\) have demonstrated a learning curve effect with CB ablation as indicated by the decline in procedure and fluoroscopy times. However,
improvement in the long-term outcome over time has been attributed to a more careful patient selection and not to operator experience *per se*.

We have now investigated the time-dependent changes in procedural parameters, complication rates, and in the 1-year clinical outcome during our initial experience with phased RF ablation.

**Methods**

*Study population*

The present study included consecutive patients who underwent PVI with phased RF ablation for paroxysmal or persistent AF at our center between November 01, 2009 and April 30, 2012 and who had regular follow-up during the first 12 months post-ablation. Exclusion criteria included previous AF ablation, long-standing persistent AF, hyper- and hypothyroidism, significant valvular heart disease, heart failure of NYHA class III or IV, a left ventricular (LV) ejection fraction ≤ 40%, a left atrial (LA) diameter exceeding 50 mm, a LA thrombus, unstable angina or myocardial infarction within the last 3 months, severe chronic obstructive pulmonary disease, known bleeding disorders, contraindication to oral anticoagulation and pregnancy. All participating patients signed the informed consent form prior to the procedure.

*Patient preparation and pre-procedural evaluation*

Patients were admitted to the hospital 1 or 2 days prior to the procedure. Those on oral anticoagulation with a vitamin K antagonist (VKA) continued to take the drug and the procedure was performed with an international normalized ratio in the therapeutic range. For all other patients, low molecular weight heparin was started twice daily in a weight-adjusted dose and administered until 12 hours prior to the procedure. All patients scheduled for ablation were examined by transesophageal echocardiography within 24 hours to rule out an intracardiac thrombus. The LA and PV anatomies were assessed by means of multislice cardiac CT imaging before the ablation.

*Ablation procedure with phased RF and the PVAC*

Ablation procedures were performed under conscious sedation with midazolam and fentanyl. Decapolar (BARD Electrophysiology Inc., Lowell, MA, USA) and quadripolar (Woxx 4 J, 6F, Biotronik, SE & Co. KG, Berlin, Germany) catheters were advanced from the
femoral vein and positioned into the coronary sinus and the right ventricle. Surface electrocardiograms and bipolar intracardiac electrograms were registered with a Prucka, GE Medical digital recording system. A single transseptal puncture was performed under fluoroscopic guidance, by a standard technique using a Swartz SL (St.Jude Medical, Minneapolis, Mn, USA) transseptal sheath. This sheath was then exchanged for a deflectable 12 Fr CryoCath sheath (Medtronic CryoCath LP, Kirkland, Quebec, Canada) to be used for guiding in left atrium under continuous flush with heparinized saline. Immediately after the transseptal puncture, a 150 IU/kg body weight intravenous (iv) heparin bolus was administered, followed by a continuous infusion to maintain a minimum ACT target level of >300 s during ablations. Additional iv boluses of 2000-5000 IU heparin were administered as needed to attain the minimum target ACT level. This heparinization scheme was the same regardless the ongoing rhythm (sinus rhythm versus AF) during ablation.

The technical specifications of the circular, multipolar Pulmonary Vein Ablation Catheter (PVAC), the GENius RF generator (Medtronic Inc., Minneapolis, MN, USA) and the methodology used in our center have been described in detail. \(^{16-17}\) Briefly, the catheter was advanced through the FlexCath sheath over a 0.032-inch guidewire (BARD Electrophysiology Inc., Lowell, MA, USA), which was positioned selectively in each PV. The electrical conduction properties of the PV were assessed on the basis of the signals recorded by the PV AC electrodes after placement inside the ostium. Before the first RF delivery, the positions of the electrodes relative to the PV ostium were always confirmed by means of selective contrast injection through the FlexCath sheath. Care was taken always to apply the RF outside the vein in the antral region, targeting potentials of high amplitude on as many electrodes as possible for each application. Common ostia were isolated by inserting the guide wire into the different side branches and ablating subsequent segments of the targeted veins. The PVAC was connected to the GENius RF generator, which is capable of delivering RF current in different bipolar/unipolar mode ratios to any or all of the five bipolar channels in a duty-cycled mode. The target temperature was 60 °C, measured separately for all bipoles. Bipolar/unipolar RF delivery was usually started at a ratio of 4:1 for each PV and changed to a bipolar/unipolar proportion of 2:1 for a deeper lesion when a sufficient reduction in local electrogram amplitude could not be achieved after multiple RF deliveries. RF energy was applied for 60 s, usually 3-4 times per PV, until PVI was achieved. The PV conduction was reassessed after each RF application, the electrodes being advanced inside the ostium.

**Follow-up**
Patients were usually discharged within 2 days after the ablation. Following the procedure a vitamin K antagonist was continued for at least 3 months. Patients taking an AAD before the procedure continued the medication for 3 months post-ablation. It was then discontinued if the patient was free of an AF relapse. VKA was discontinued 3 months after the ablation only in patients with a CHADS-VASC score of 1 or below, while those patients with a higher stroke risk were kept on oral anticoagulation regardless the results of postablation arrhythmia monitoring. Follow-up visits were scheduled at 6 weeks, and 3, 6, 9 and 12 months post-procedure.

The 12-lead ECG was checked at each follow-up. Additionally, 24-h Holter monitoring was performed at least twice, and also transtelephonic monitoring 3 times for 14-21 days, during the first 6 months. Patients were asked to transmit their rhythm at least 2-3 times a day, and always in the event of any palpitation. During non-telemetry periods of follow-up, patients were encouraged to visit the nearest hospital or outpatient facility to document their rhythm on an ECG whenever they felt any abnormality of their heart beat. Arrhythmia recurrence was defined as any atrial arrhythmia lasting for 30 s or longer. The definition of long-term success was freedom from any atrial arrhythmia without any AAD, after one procedure with a blanking period in the first 3 months.

End points
The acute endpoint of the procedure was the electrical isolation of all PVs, as confirmed by an entrance block.

Long-term efficacy was defined as freedom from any atrial arrhythmia without a Class I or Class III AAD after one procedure at 12 month follow-up with a blanking period in the first 3 months.

Significant periprocedural complications were defined as any injury which resulted in death or had long-term sequel, required an immediate intervention or prolonged hospital stay.

Statistical analysis
The study period was divided into tierces to include the same number of patients who underwent AF ablation within each tierce. Clinical characteristics, procedural and follow-up data for subjects in each tierce were presented using numbers and frequencies (%) for categorical variables and means with standard deviations (SD) for continuous variables. Statistical calculations were performed with IBM SPSS Statistics 20 Software.
The distribution was examined with Kolmogorov-Smirnov test. Discrete variables were analyzed using Chi-square test. ANOVA (Analysis of variances) and Kruskal-Wallis were used for comparisons of groups. Cox regression as univariate test was used to estimate the hazard ratio. P value less than 0.05 was considered significant.

Results

A total of 132 patients were enrolled. Preablation clinical characteristics of the first, second and third 44 patients who underwent PVI with phased RF ablation are displayed in Table 1. Significant differences between the 3 tierces were found in the age and in the LA size only.

A total of 177 PVs were successfully isolated out of the 177 targeted in Tierce 1, while 173/176 and 169/171 in Tierces 2 and 3, respectively (p>0.05).

All PVs were successfully isolated in 44 (100%), 41 (93.8 %) and 42 (95.5 %) patients in Tierce 1, 2 and 3, respectively, (p=0.233). However, the number of RF applications (per PV) needed for isolation demonstrated a significant decrease with experience (6.22 SD: 2.43; 4.65 SD:.1.32 and 4.12 SD: 1.2 in Tierce 1, 2 and 3, respectively; p<0.001). Procedure times demonstrated a trend for lower values in Tierces 2 and 3 but the difference did not reach the level of statistical significance. In contrast, a significant decrease in fluoroscopy times was demonstrated (Figure 1).

Pericardial tamponade requiring percutaneous subxiphoid drainage occured in the 104th consecutive patient (Tierce 3) as the only significant procedural complication.

Atrial arrhythmia-free survival rates without AAD at 12 months postablation were 68%, 75%, and 70.75% in Tierce 1, Tierce 2 and Tierce 3, respectively (p=0.772). On Cox proportional hazard analysis which included clinical and procedural variables no significant predictor of arrhythmia recurrence was demonstrated (Table 2).

Discussion

Main findings

This study assessed the effects of learning curve on procedural parameters and long-term success during phased RF ablation with the PVAC. Fluoroscopy time and the number of RF applications required for successful PVI declined progressively with more experience, and
a similar trend was observed for procedure time. Importantly, no learning curve effect was demonstrated in the success and complication rates.

**Previous studies on learning curve in AF ablation**

Although AF ablation is considered technically more challenging compared with other ablation procedures, very limited data have been published on the significance of operator experience in relation to the safety and efficacy of the procedure. The first study that specifically addressed the importance of the learning curve during AF ablation was published by Sairaku\(^\text{14}\) who reported on the results of the first 208 consecutive PVIs with point-by-point focal RF ablation in a medium-volume center. A significant learning curve effect not only in procedure and fluoroscopy times, but also in complication rates and in the arrhythmia-free survival at 6-month follow-up has been demonstrated. In another study summarizing the experience on 641 AF ablations at Johns Hopkins Hospital complication rates were 9 % during the first 100 and 4.3 % during the subsequent 541 procedures\(^\text{18}\). World-wide survey\(^\text{19}\) and the most recent consensus statement on AF ablation\(^\text{1}\) also suggest that safety and efficacy results are better in centers performing more than 100 procedures annually. These recommendations are largely based on the experience gained with focal RF ablation.

Single-shot AF ablation techniques have been introduced to simplify and speed up PVI procedures. Available data on the influence of operator experience as related to the safety and efficacy results with these simplified approaches are also limited. Wójcik et al.\(^\text{15}\) reported on the procedural experience gained over 8 years with CB ablation in a high-volume center. A continuous decrease in fluoroscopy and procedure times was observed in each subsequent year and on multivariate analysis both the year of procedure and the preablation ALARMEc (Atrial fibrillation type, LA size, Renal insufficiency, MEtabolic syndrome, cardiomyopathy) risk score were independent predictors of procedure and fluoroscopy times. However, no significant decrease in complication rate over the 8-year period has been demonstrated. The overall success rate at 12 months postablation was 73 % which improved with each subsequent year however this was related to the gradual fall in the ALARMEc risk score. In another single center study, the learning curves for PVI with phased RF ablation versus with the Cardiofocus Laser Balloon (LB) have been compared in the first 50 patients undergoing PVI with each technology\(^\text{20}\). Procedure and fluoroscopy times decreased with time with both technologies. Atrial arrhythmia recurrence 6 months after a single procedure improved significantly from the first triace (31.2%) to the second (17.6%) and to the third (0 %) with LB but no clear improvement was found with phased RF ablation.
These published data are in line with our results and suggest that the influence of operator experience on clinical success and procedural complications of AF ablation may be less significant with a single-shot as compared with the conventional method. This is further supported by the initial experience of a center with AF ablation\(^ {21}\). The first 109 patients at this center underwent PVI with either 3D guided focal RF or with phased RF ablation. The six-month success rate was significantly higher with phased RF (68 %) as compared with focal (39 %) ablation, while complication rates were similar. Procedure and fluoroscopy times were also significantly shorter with phased RF ablation.

Although studies on direct comparison of PVAC with point-by-point PVI are limited, similar success rates have recently been reported with the two techniques\(^ {22}\). In a multicenter prospective randomized comparison the arrhythmia-free survival at 12 months was 56% with wide-area circumferential ablation and 60 % with phased RF ablation in patients with paroxysmal AF. The efficacy of PVI with the PVAC without any other left atrial ablation target in more chronic forms of AF is yet to be determined\(^ {23}\). Although the TTOP-AF study evaluated phased RF ablation in such patient cohort, other ablation catheters (MAAC=Multi-Array Ablation Catheter and MASC=Multi-Array Septal Catheter) to target low amplitude high frequency complex fractionated electrograms on the left atrial posterior wall and septum were also used in that study. The ongoing Victory-AF trial is currently enrolling patients with persistent and long-standing persistent AF using PVAC GOLD the new generation of the PVAC catheter\(^ {24}\).

**Potential implications for clinical practice**

Available data suggest that the learning curve in PVI and the influence of previous operator experience on relevant procedural and clinical endpoints might be ablation technology-dependent. Ablation with a single-shot device can be performed not only with shorter procedure and fluoroscopy times as compared with focal ablation, but also with more satisfactory clinical outcome by a well trained electrophysiologist who is proficient in transseptal catheterization and left atrial ablation but is in the early phase of his AF ablation practice. Further, any of these simplified approaches might be a reasonable choice for lower volume centers as a regular performance of a higher number of procedures is required not only to develop but also to maintain the adequate technical skills with point-by-point ablation.

**Limitations of the study**
This study has several limitations. First, this was a single center, observational patient cohort study including a relatively small number of patients thereby limiting the statistical power. There was however no selection bias for the study as consecutive patients undergoing AF ablation with phased RF were enrolled. Second, the main operator in all procedures had gained previous, although limited experience with CB ablation before he started this study, which required somewhat similar skills as ablation with the PVAC, therefore these results may not necessarily apply to what could be achieved by someone with absolutely no experience in AF ablation. Third, although high incidence of new silent cerebral ischemia detected by diffusion-weighted magnetic resonance imaging was reported after phased RF ablations\textsuperscript{25,26}, this subclinical complication was not assessed in this study. However, most recent data indicated a very substantial reduction in silent cerebral embolisation thanks to some technical and procedural modifications in phased RF ablation\textsuperscript{27,28}.

Conclusions

This study investigated the time-dependent changes in procedural parameters, complication rates, and in the 1-year clinical outcome during our initial experience with circular, multipolar phased RF ablation. A learning curve effect was demonstrated in fluoroscopy times and in the number of RF applications but not in the acute success and in the long-term arrhythmia-free survival.

Statement of competing interests: nothing to declare

References


24. ClinicalTrials.gov identifier: NCT01693120


Table 1: Baseline clinical characteristics in each Tierce

<table>
<thead>
<tr>
<th>Patient characteristic</th>
<th>Tierce 1</th>
<th>Tierce 2</th>
<th>Tierce 3</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (±SD)</td>
<td>55.12 ± 10.13</td>
<td>54.85 ± 10</td>
<td>59.82 ± 10.45</td>
<td>0.04</td>
</tr>
<tr>
<td>Male / female (n)</td>
<td>33/11</td>
<td>31/13</td>
<td>28/16</td>
<td>0.506</td>
</tr>
<tr>
<td>Type of AF (n, %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persistent</td>
<td>10 (22.72%)</td>
<td>9 (20.45%)</td>
<td>3 (6.82%)</td>
<td>0.096</td>
</tr>
<tr>
<td>Medical history:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (n, %)</td>
<td>31 (70.45%)</td>
<td>29 (65.9%)</td>
<td>36 (81.8%)</td>
<td>0.225</td>
</tr>
<tr>
<td>Diabetes (n, %)</td>
<td>5 (11.36%)</td>
<td>8 (18.18%)</td>
<td>7 (15.9%)</td>
<td>0.662</td>
</tr>
<tr>
<td>Coronary artery disease (n, %)</td>
<td>4 (9.1%)</td>
<td>6 (13.63%)</td>
<td>9 (20.45%)</td>
<td>0.311</td>
</tr>
<tr>
<td>Left atrial diameter (mm ± SD)</td>
<td>40.61 ± 4.6</td>
<td>43.16 ± 4.98</td>
<td>42.11 ± 4.35</td>
<td>0.039</td>
</tr>
<tr>
<td>Left ventricular ejection fraction (%± SD)</td>
<td>55.45 ± 6.1</td>
<td>54.52 ± 7.69</td>
<td>55.43 ± 7.95</td>
<td>0.792</td>
</tr>
</tbody>
</table>

AF: atrial fibrillation
Table 2: Cox regression analysis on 12-month arrhythmia-free survival

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>AF free survival 95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>1.352</td>
<td>0.589 – 3.106</td>
<td>0.477</td>
</tr>
<tr>
<td>Age</td>
<td>1.019</td>
<td>0.978 – 1.061</td>
<td>0.376</td>
</tr>
<tr>
<td>Persistent AF</td>
<td>1.291</td>
<td>0.542 – 3.078</td>
<td>0.564</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.970</td>
<td>0.390 – 2.409</td>
<td>0.947</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>1.266</td>
<td>0.467 – 3.437</td>
<td>0.643</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.808</td>
<td>0.301 – 2.165</td>
<td>0.671</td>
</tr>
<tr>
<td>Left atrial diameter</td>
<td>1.001</td>
<td>0.925 – 1.083</td>
<td>0.985</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>0.988</td>
<td>0.940 – 1.038</td>
<td>0.629</td>
</tr>
<tr>
<td>Total procedure time</td>
<td>0.996</td>
<td>0.987 – 1.005</td>
<td>0.372</td>
</tr>
<tr>
<td>Fluoroscopy time</td>
<td>1.026</td>
<td>0.986 – 1.068</td>
<td>0.207</td>
</tr>
<tr>
<td>Group I</td>
<td></td>
<td></td>
<td>0.839</td>
</tr>
<tr>
<td>Group II</td>
<td>0.777</td>
<td>0.337 – 1.793</td>
<td>0.555</td>
</tr>
<tr>
<td>Group III</td>
<td>0.898</td>
<td>0.383 – 2.106</td>
<td>0.805</td>
</tr>
</tbody>
</table>

Figure 1. Procedure and fluoroscopy times in each Tierce